Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Mepolizumab

Research Leaders

8 sponsors active, led by University Hospital of Pisa

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Unknown1

Completed1

Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials

NCT07786870Recruiting

Expression of TSLP Isoforms in Asthma

NCT05114447Unknown

Severe/Uncontrolled Asthma From General Population to Clinical Setting: Update and Follow-up of the RItA Registry

NCT05441059CompletedPrimary

Use of Nucala in Severe Asthma

Showing all 3 trials

Research Network

Common Treatments

Mepolizumab1
Routine Medical Care1
Telephone Interview1
No Intervention Observational Cohort1

Active Sponsors

University Hospital of Pisa1
University Of Perugia1
GSK1
Frisius Medisch Centrum1
National Research Council, Institute of Clinical Physiology, Italy1

Asthma Severe Persistent Uncontrolled